SNY
NASDAQHealthcareLoading…
Sanofi - American Depositary Shares
Sector: Healthcare•United States•Market Cap: $112.1B
Related News
Latest stories connected to SNY
- RS 75EU regulator backs Sanofi's injectable version of blood cancer drugReuters•4d ago•Original source
- RS 75Sanofi launches innovation and operation centre in ChinaReuters•Mar 20, 2026•Original source
- RS 75Sanofi: An Undervalued Stock For Long-Term Dividend Growth InvestorsSeeking Alpha•Mar 16, 2026•Original source
- RS 75Sanofi: Information concerning the total number of voting rights and shares - February 2026GlobeNewsWire•Mar 12, 2026•Original source
- RS 75Brazil drugmaker EMS eyes overseas deals after buying Sanofi unitReuters•Mar 10, 2026•Original source
- RS 75Need Growing EPS And Dividends? Prescribe SanofiSeeking Alpha•Mar 6, 2026•Original source
- RS 75Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent directorGlobeNewsWire•Mar 5, 2026•Original source
- RS 75Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial ReportGlobeNewsWire•Mar 4, 2026•Original source
- RS 75Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in JapanZacks Investment Research•Mar 3, 2026•Original source
Financials
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Revenue | 46.72B | 44.29B | 41.62B | 40.56B | 39.17B | 37.37B | 37.63B | 35.68B | 36.22B | 34.70B |
| Cost of Revenue | 12.92B | 13.21B | 12.63B | 11.88B | 12.26B | 12.16B | 11.98B | 11.44B | 11.61B | 10.70B |
| Gross Profit | 33.79B | 31.08B | 28.99B | 28.68B | 26.92B | 25.21B | 25.65B | 24.24B | 24.61B | 24.00B |
| Research and Development Expenses | 7.84B | 7.39B | 6.51B | 6.50B | 5.69B | 5.53B | 6.02B | 5.89B | 5.47B | 5.17B |
| General and Administrative Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling and Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General and Administrative Expenses | 9.54B | 9.18B | 8.93B | 8.74B | 9.55B | 9.39B | 9.88B | 9.86B | 10.07B | 9.48B |
| Other Expenses | 10.06B | 7.25B | 6.59B | 3.28B | 3.55B | -3.82B | 6.70B | 3.81B | 3.26B | 2.81B |
| Operating Expenses | 27.45B | 23.83B | 22.03B | 18.52B | 18.79B | 11.10B | 22.60B | 19.57B | 18.80B | 17.46B |
| Cost and Expenses | 40.37B | 37.03B | 34.66B | 30.40B | 31.05B | 23.26B | 34.58B | 31.00B | 30.42B | 28.16B |
| Net Interest Income | -162.33M | -165.04M | 17.68M | -215.84M | -374.24M | -396.41M | -446.57M | -412.12M | -279.47M | -340.47M |
| Interest Income | 378.45M | 457.53M | 530.50M | 168.96M | 3.13M | 34.43M | 89.71M | 74.37M | 53.97M | 59.03M |
| Interest Expense | 540.78M | 622.58M | 512.82M | 384.80M | 377.37M | 430.84M | 536.27M | 486.48M | 333.43M | 399.50M |
| Depreciation and Amortization | 3.21B | 3.59B | 3.78B | 3.42B | 3.35B | 3.30B | 7.45B | 4.28B | 3.69B | 3.30B |
| EBITDA | 12.68B | 11.03B | 11.39B | 13.51B | 11.54B | 17.88B | 10.66B | 9.18B | 9.64B | 9.90B |
| EBIT | 9.47B | 7.45B | 6.96B | 10.40B | 8.19B | 14.21B | 3.22B | 4.90B | 5.95B | 6.60B |
| Non Operating Income Excluding Interest | -3.13B | -195.00M | -1.00M | -240.00M | -61.00M | -99.00M | -166.00M | -224.00M | -147.00M | -68.00M |
| Operating Income | 6.34B | 7.25B | 6.96B | 10.16B | 8.13B | 14.11B | 3.05B | 4.68B | 5.80B | 6.53B |
| Total Other Income Expenses Net | -324.00M | -494.00M | -845.00M | -170.00M | -289.00M | 24.00M | -44.00M | 228.00M | -188.00M | -720.00M |
| Income Before Tax | 6.02B | 6.76B | 6.12B | 9.99B | 7.84B | 14.14B | 3.01B | 4.90B | 5.62B | 5.81B |
| Income Tax Expense | 1.04B | 1.20B | 1.02B | 1.91B | 1.56B | 1.81B | 121.00M | 481.00M | 1.72B | 1.32B |
| Net Income From Continuing Operations | 4.98B | 5.55B | 5.10B | 8.08B | 6.28B | 12.33B | 2.89B | 4.42B | 3.89B | 4.49B |
| Net Income From Discontinued Operations | 2.87B | 64.00M | 338.00M | 401.00M | 0 | 0 | -101.00M | -13.00M | 4.64B | 314.00M |
| Other Adjustments To Net Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 7.81B | 5.50B | 5.40B | 8.37B | 6.22B | 12.31B | 1.86B | 4.31B | 8.43B | 4.71B |
| Net Income Deductions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrom Line Net Income | — | — | — | — | — | — | — | — | — | — |
| EPS | 2.03 | 2.19 | 2.15 | 3.19 | 2.49 | 4.91 | 1.14 | 1.73 | 1.5 | 1.83 |
| EPS Diluted | 2.03 | 2.19 | 2.15 | 3.18 | 2.49 | 4.91 | 1.14 | 1.73 | 3.36 | 1.83 |
| Weighted Average SHS Out | 2.44B | 2.50B | 2.50B | 2.50B | 2.50B | 2.51B | 2.50B | 2.49B | 2.51B | 2.57B |
| Weighted Average SHS Out Dil | 2.44B | 2.50B | 2.51B | 2.50B | 2.50B | 2.51B | 2.50B | 2.49B | 2.51B | 2.57B |
| Fiscal Year (FMP) | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K |
| Gross Profit Margin | 0.72 | 0.7 | 0.7 | 0.71 | 0.69 | 0.67 | 0.68 | 0.68 | 0.68 | 0.69 |
| R&D to Revenue | 0.17 | 0.17 | 0.16 | 0.16 | 0.15 | 0.15 | 0.16 | 0.17 | 0.15 | 0.15 |
| SG&A to Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Burden | 0.64 | 0.91 | 0.88 | 0.96 | 0.96 | 0.99 | 0.93 | 1 | 0.94 | 0.88 |
| EBIT Margin | 0.2 | 0.17 | 0.17 | 0.26 | 0.21 | 0.38 | 0.09 | 0.14 | 0.16 | 0.19 |
| EBITDA Margin | 0.27 | 0.25 | 0.27 | 0.33 | 0.29 | 0.48 | 0.28 | 0.26 | 0.27 | 0.29 |
| EBT per EBIT | 0.95 | 0.93 | 0.88 | 0.98 | 0.96 | 1 | 0.99 | 1.05 | 0.97 | 0.89 |
| Effective Tax Rate | 0.17 | 0.18 | 0.17 | 0.19 | 0.2 | 0.13 | 0.04 | 0.1 | 0.31 | 0.23 |
| Tax Burden | 1.3 | 0.82 | 0.88 | 0.84 | 0.79 | 0.87 | 0.92 | 0.88 | 1.5 | 0.81 |
| Cont. Operations Profit Margin | 0.11 | 0.13 | 0.12 | 0.2 | 0.16 | 0.33 | 0.08 | 0.12 | 0.11 | 0.13 |
| Bottom Line Profit Margin | 0.11 | 0.13 | 0.13 | 0.21 | 0.16 | 0.33 | 0.07 | 0.12 | 0.23 | 0.14 |
| Operating Cycle | 643.99 | 348.29 | 376.21 | 371.94 | 350.75 | 347.93 | 341.38 | 334.27 | 301.71 | 330.28 |
| Fwd PEG Ratio | -1.66 | 11.3 | -0.65 | 0.48 | -0.36 | 0.02 | -1.2 | 1.46 | -0.59 | 1.81 |
| Earnings Yield | 0.08 | 0.05 | 0.05 | 0.07 | 0.06 | 0.12 | 0.02 | 0.05 | 0.09 | 0.05 |
| Income Quality | 1.38 | 1.65 | 1.9 | 1.26 | 1.69 | 0.6 | 4.17 | 1.29 | 0.87 | 1.66 |